-
51.发明申请Novel hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules 审中-公开新型水凝胶分离的耳蜗制剂，制备方法及其用于递送生物相关分子的用途公开(公告)号：US20030228355A1
公开(公告)日：2003-12-11
申请号：US10421358
申请日：2003-04-23
Applicant: BioDelivery Sciences International, Inc. , University of Medicine and Dentistry of New Jersey
Inventor： Leila Zarif , Tuo Jin , Ignacio Segarra , Raphael J. Mannino
IPC: A61K048/00 , A61K039/00 , A61K009/127 , C12N015/88
CPC classification number: A61K9/1274 , A61K31/07 , A61K31/11 , A61K31/20 , A61K31/472 , A61K31/496 , A61K31/704 , A61K31/7048 , A61K31/713 , A61K36/54 , A61K38/13 , Y10S436/829 , Y10S514/966 , Y10S514/967 , Y10T428/2984
Abstract: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2null or Zn2null, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.
Abstract translation: 一种生产小型，基于脂质的耳蜗的方法。 耳蜗源自脂质体，其悬浮在水性两相聚合物溶液中，使得能够通过相分离差异分配极性分子基结构。 用带正电荷的分子如Ca 2+或Zn 2+处理的含脂质体的两相聚合物溶液形成粒度小于1微米的耳蜗沉淀物。 该方法可用于产生含有生物相关分子的耳蜗细胞。
-
公开(公告)号：US20030176343A1
公开(公告)日：2003-09-18
申请号：US10339924
申请日：2003-01-09
Inventor： Eric H. Rubin , Ahamed Saleem , Zeshaan Rasheed , Paul Haluska JR.
IPC: C12Q001/68 , G01N033/574 , A61K048/00 , A61K038/17 , C07K016/40
CPC classification number: C07K14/4703 , A61K2039/505 , C07K16/18
Abstract: Topors and topors antibody can be used to manipulate the presence and function of both Top1 and p53 in cells, thus controlling the function of the Top1 and p53 proteins. Topors is implicated in prevention of tumorigenesis through its role in DNA repair and preventing faulty or mutated DNA from replicating. Topors can be used therapeutically as a medicament and topors DNA can be used in gene therapy. Topors antibody may be used to detect the presence of cancer by screening for the absence of topors in a given cell or tissue sample. Kits comprising the topors antibody are also contemplated.
Abstract translation: Topors和Topors抗体可用于操纵细胞中Top1和p53的存在和功能，从而控制Top1和p53蛋白的功能。 参与者通过其在DNA修复中的作用和防止错误或突变的DNA复制来预防肿瘤发生。 导向剂可以作为药物治疗使用，并且拓扑DNA可用于基因治疗。 Topors抗体可用于通过筛选给定细胞或组织样品中不存在顶部物来检测癌症的存在。 还考虑了包含顶体抗体的试剂盒。
-
53.发明申请Method of modulating the efficiency of translation termination and degradation of aberrant mRNA involving a surveillance complex comprising human Upf1p,eucaryotic release factor 1 and eucaryotic release factor 3 审中-公开涉及包含人Upf1p，真核释放因子1和真核释放因子3的监测复合物的翻译终止和异常mRNA降解效率的方法公开(公告)号：US20030032158A1
公开(公告)日：2003-02-13
申请号：US10138784
申请日：2002-05-03
Inventor： Stuart Peltz , Kevin Czaplinski , Youmin Weng
IPC: C12N009/02 , C07K016/40
CPC classification number: C12N9/14 , A61K38/00 , C07K14/395 , C07K14/4702
Abstract: Provided are novel methods and assays to identify agents and compositions that modulate the ability of the eukaryotic surveillance complex to effect translation termination and degradation of aberrant mRNA.
Abstract translation: 提供了用于鉴定调节真核监控复合物影响翻译终止和异常mRNA降解的能力的试剂和组合物的新方法和测定。
-
54.发明申请Cell type specific gene transfers using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins 审中-公开使用含有抗体包膜融合蛋白和野生型包膜融合蛋白的逆转录病毒载体进行细胞型特异性基因转移公开(公告)号：US20030017140A1
公开(公告)日：2003-01-23
申请号：US10211488
申请日：2002-08-02
Inventor： Ralph C. Dornburg
IPC: A61K048/00 , A61K039/395 , C12N015/867
CPC classification number: C12N15/86 , A61K38/00 , A61K47/6901 , A61K48/00 , C07K14/005 , C07K16/30 , C07K16/44 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/04 , C07K2319/30 , C07K2319/40 , C07K2319/75 , C12N15/62 , C12N2740/13022 , C12N2740/13043 , C12N2740/13045 , C12N2810/60 , C12N2810/6054 , C12N2810/859
Abstract: A method of infecting target cells with retroviral vector particles having target cell specificity. The retroviral vector particles have a chimeric envelope protein consisting of an antigen binding site of an antibody or another peptide, fused to the envelope protein the retroviral vector. The antigen binding site or other peptide disrupts the natural viral receptor binding site. The method includes producing the retroviral vector and contacting the vector with the target cell such that the vector is internalized by the cell.
Abstract translation: 用具有靶细胞特异性的逆转录病毒载体颗粒感染靶细胞的方法。 逆转录病毒载体颗粒具有由抗体结合位点或与包膜蛋白融合的逆转录病毒载体的另一肽组成的嵌合包膜蛋白。 抗原结合位点或其他肽破坏天然病毒受体结合位点。 该方法包括产生逆转录病毒载体并使载体与靶细胞接触，使得载体被细胞内化。
-
公开(公告)号：WO2013016512A1
公开(公告)日：2013-01-31
申请号：PCT/US2012/048296
申请日：2012-07-26
Inventor： MADURA, Kiran
IPC: C12Q1/37
CPC classification number: C12Q1/37 , C12Q1/6888 , G01N33/573 , G01N2800/365
Abstract: Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the kits and assays are also disclosed.
Abstract translation: 公开了用于确定一种或多种动物是否具有乳腺炎和监测动物以及它们产生的乳的质量的方法和试剂盒。 公开的试剂盒和测试测定用于测定蛋白酶体及其蛋白质的量，蛋白酶体酶的活性，蛋白酶体的结合和调节蛋白的量以及泛素化蛋白的量。 还公开了用于试剂盒和试验的组分和试剂。
-
Patent Agency Ranking56.发明申请DIAGNOSTIC BIOMARKER PROFILES FOR THE DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE 审中-公开用于检测和诊断阿尔茨海默病的诊断生物标志物
公开(公告)号：WO2013010003A1
公开(公告)日：2013-01-17
申请号：PCT/US2012/046502
申请日：2012-07-12
Inventor： NAGELE, Robert G.
IPC: G01N33/53
CPC classification number: G01N33/6896 , G01N33/54306 , G01N33/564 , G01N2800/2821
Abstract: The present invention provides methods, compositions and kits for the detection of Alzheimer's disease (AD) diagnostic biomarkers, for the diagnosis of AD, for the identification of a subject at risk for developing AD, and for the generation of patient- specific AD diagnostic biomarker profiles.
Abstract translation: 本发明提供了用于检测阿尔茨海默氏病（AD）诊断生物标志物，用于诊断AD的方法，组合物和试剂盒，用于鉴定患有AD发展风险的受试者以及用于产生患者特异性AD诊断生物标志物 配置文件。
-
公开(公告)号：WO2012135868A3
公开(公告)日：2012-10-04
申请号：PCT/US2012/031918
申请日：2012-04-02
Inventor： WEISLEDER, Noah , MA, Jianjie
IPC: A61K38/17 , A61K38/16 , A61K48/00 , A61K31/7105 , A61P9/00
Abstract: Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue.
-
58.发明申请DETECTION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN CANCER AND NORMAL CELLS 审中-公开检测癌症和正常细胞中人类内源性逆转录酶表达
公开(公告)号：WO2012118974A2
公开(公告)日：2012-09-07
申请号：PCT/US2012/027289
申请日：2012-03-01
Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY , TSIAGBE, Vincent, K. , OLD, Lloyd , LI, Yu
Inventor： TSIAGBE, Vincent, K. , OLD, Lloyd , LI, Yu
IPC: C12Q1/70
CPC classification number: C07K16/1063 , C07K16/1036 , C07K16/30 , C07K2317/34 , C07K2317/55 , C12Q1/703 , G01N33/56988 , G01N33/574 , G01N33/57426
Abstract: The invention relates to human endogenous retrovirus env (HERV-WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.
Abstract translation: 本发明涉及人内源性逆转录病毒env（HERV-WL）多肽，核苷酸序列，HERV-WL抗体，检测癌症的方法和确定癌症治疗有效性的方法。
-
59.发明申请NOVEL METHOD OF CANCER DIAGNOSIS AND PROGNOSIS AND PREDICTION OF RESPONSE TO THERAPY 审中-公开癌症诊断和预后的新方法及对治疗的预测
公开(公告)号：WO2012078648A2
公开(公告)日：2012-06-14
申请号：PCT/US2011/063553
申请日：2011-12-06
Inventor： ZARBL, Helmut , GRAHAM, Jessica
IPC: G01N33/574
CPC classification number: C12Q1/6886 , A61K38/1709 , C07K14/47 , G01N33/57484 , G01N33/57496 , G01N2800/50 , G01N2800/52
Abstract: The invention relates to pharmaceutical compositions comprising of FRY polypeptides and nucleotides, methods to treat cancer, methods to diagnose cancer, and methods to determine the effectiveness of the treatment of cancer, as well as methods to differentiate stem cells.
Abstract translation: 本发明涉及包含FRY多肽和核苷酸的药物组合物，治疗癌症的方法，诊断癌症的方法，以及确定癌症治疗有效性的方法，以及分化干细胞的方法 细胞
-
公开(公告)号：WO2012018867A1
公开(公告)日：2012-02-09
申请号：PCT/US2011/046337
申请日：2011-08-02
Inventor： ZHAO, Xilin , DRLICA, Karl
IPC: A01N37/18
CPC classification number: A61K33/00 , A01N59/00 , A61M16/12 , A01N2300/00 , A61K2300/00
Abstract: A gas mixture for treatment of a mycobacterial infection and methods thereof, wherein the gas mixture comprises hydrogen. In certain applications, the gas mixture further comprises oxygen and optionally an inert or anaerobic gas, preferably selected from the group consisting of nitrogen, helium, argon, carbon dioxide, and mixtures thereof. The methods for treatment comprise direct inhalation of the gas mixture comprising hydrogen and oxygen, intubation of a patient with a double lumen endotracheal tube thereby supplying one lung with an anaerobic gas, and administration of a gas mixture comprising hydrogen and oxygen in a hyperbaric setting. Also provided is a method of sterilization of a mycobacterium-contaminated surface comprising administration of the hydrogen-containing gas mixture.
Abstract translation: 一种用于治疗分枝杆菌感染的气体混合物及其方法，其中所述气体混合物包含氢气。 在某些应用中，气体混合物还包含氧气和任选的惰性或厌氧气体，优选选自氮气，氦气，氩气，二氧化碳及其混合物。 治疗方法包括直接吸入包含氢气和氧气的气体混合物，将患者插入双腔气管插管，从而向厌氧气体供应一个肺，以及在高压环境中施用包含氢气和氧气的气体混合物。 还提供了包含施用含氢气体混合物的分枝杆菌污染表面的灭菌方法。
-
-
-
-
-
-
-
-
-
Search Results
459
records
(took 0.035 seconds)
